Having looked at the announcement again there are a couple of things that struck me.
Firstly, the tumour size does not appear to decrease in the chart. In the previous trial of pancreatic cancer last year it could be seen that the tumour actually decreased in size, before increasing again. Does anyone have an explanation?
Secondly, I personally didn't think the low dose of Dep irinotecan was that much different to standard irinotecan, regardless of what the text wants us to believe. That is to say, it was not a significant improvement.
Thirdly, and back to frivolity again folks, why call the two thirds MTD dose of Dep irinotecan the “high” dose? What if they want to dose at the full strength of standard irinotecan in the future? Do they call that the “extreme” dose? Hardly inspirational, is it? I think they should have called it the “medium dose”. IMO.
These are still great results in comparison to what is currently available.
SPL Price at posting:
$1.29 Sentiment: Buy Disclosure: Held
